Milestone Pharmaceuticals is trading 5.11% up now at $1.24 after announcing new longitudinal-study findings on how PSVT affects patients’ daily lives and quality of life between episodes.
- Data will be presented at the European Society of Cardiology Congress on August 30, 2026.
- The announcement is the clearest company-specific catalyst identified for the August 27, 2026 move, although broader market sentiment is also positive.